This episode reviews a 2023 Biomedicines editorial by Gupta, Maffulli, and Jain on why red blood cells should be minimized in platelet-rich plasma. The discussion explores what hemolysis is, how it occurs, and what current research suggests about the presence of RBCs in PRP preparations used for musculoskeletal applications.

Key points include how RBC breakdown products may contribute to inflammation, oxidative stress, synovial irritation, and potential cartilage damage — and why minimizing hemolysis may help preserve the intended therapeutic benefits of PRP. 📄 Referenced Editorial: “Red Blood Cells in Platelet-Rich Plasma: Avoid If at All Possible”

If you are interested in the full study, contact [email protected]. For questions or further discussion, feel free to reach out to [email protected]. If your practice has experience managing hemolyzed PRP samples, your insights are welcome.